about
The development and deployment of Common Data Elements for tissue banks for translational research in cancer - an emerging standard based approach for the Mesothelioma Virtual Tissue BankNational Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational researchRanpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft GrowthFibulin-3 as a blood and effusion biomarker for pleural mesothelioma.Germline BAP1 mutations predispose to malignant mesotheliomaMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibCrocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamstersTranslation research: from accurate diagnosis to appropriate treatmentSerum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysisBRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma.Consensus report of the 2015 Weinman International Conference on MesotheliomaMapping the hallmarks of lung adenocarcinoma with massively parallel sequencingMESOMARK: a potential test for malignant pleural mesotheliomaBiomarkers and prognostic factors for mesotheliomaAsbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cellsMinimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesotheliomaTNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesisDNA methylation profile of 28 potential marker loci in malignant mesotheliomaNational Mesothelioma Virtual Bank: A Platform for Collaborative Research and Mesothelioma Biobanking Resource to Support Translational ResearchDNA copy number gains in malignant pleural mesotheliomaLatest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapiesCombined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700sNew insight into the molecular mechanisms of the biological effects of DNA minor groove bindersWithaferin A inhibits the proteasome activity in mesothelioma in vitro and in vivoInflammasome Modulation by Chemotherapeutics in Malignant MesotheliomaUnlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancerPositive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesotheliomaA light-diffusing device for intraoperative photodynamic therapy in the peritoneal or pleural cavity.Ectopic adrenocorticotropic hormone syndrome: localization studies in 28 patients.Medical registries: continued attempts for robust quality data.Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implicationshsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma.The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival.Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial.Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.A blood-based proteomic classifier for the molecular characterization of pulmonary nodules.Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation.microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancerValidation of a blood protein signature for non-small cell lung cancerNuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival
P50
Q23920945-4FC0FD64-18AF-45AE-AEB7-284C0F25F3F3Q23923549-9AF06B66-6408-4FF2-A38B-B52560592661Q24612464-84FF8ABF-5EBB-4C6C-A461-A6A1834F0B76Q24628879-207A867E-D8FE-4273-B86F-9EEEFB3B2F9DQ24635326-44CF893D-F0C6-402E-9232-13E71FCC3D5AQ24646295-988E0607-C8D9-4CE1-8F0D-6144D314CBD4Q24676844-D14E0958-8C75-4572-862A-77176A66CEE1Q24806201-7DC1CFD0-36E8-4E56-BC8F-E4918FCDE6A3Q26860736-3E0B83F6-492D-4133-8072-F68B937B74C3Q27851697-827882F2-522E-43D4-B220-B37270D74C28Q27908468-70A34CC1-5CE6-49BC-AEEC-62F908AE345BQ28275103-FEB006FB-C88A-4FA9-AF74-E5A30B03D179Q28287442-BE0611C3-4529-4C1E-9C23-D902B854BE1EQ28387194-3FC44652-64BB-43E9-B776-1330A37549B0Q28387699-95C37DC9-E242-4E8F-BEB1-CB770D10A9EFQ28389071-237ECD31-1644-4B84-BC82-D576179523C7Q28389414-CEE56B41-B7DA-42B5-A656-E7EA71963106Q28391214-70183954-B059-46E9-ACEE-95F8B1266BD8Q28394476-C1AF47E4-F368-4FEA-86B8-CD8AFE350356Q28395184-3E3F43F0-A329-4826-9D87-3D4B15885311Q28395597-F8CA24C1-835D-4387-8770-9C302DA7C89FQ28396964-AC886E94-645F-4EAD-8769-0C84BF5FA2F2Q28477373-A30AA490-1F46-4BCD-AB9E-3384D045FCDFQ28482366-96D6F9FF-967B-4771-8BF7-68D96B21EEBDQ28551670-FBEC3054-2F43-4BFE-AC79-56275FBBE3C1Q28744369-8449C15F-394E-4918-9C1C-3385A84DFA25Q29248126-20DBFA3F-9AD6-4D93-A2BE-B43C584EF92BQ30662925-C2D211FB-3B1C-4B1A-BE20-644F062D0D7DQ30873010-7DC3F67C-E1DF-45CB-9A8A-4E31BDD83425Q33587226-619C15BA-D6A8-4432-814A-FAD026535B74Q33683134-4596577B-7123-424E-AC14-D209A95FFBB8Q33699231-2DA64BCD-E697-4B75-A472-D559A2234D70Q33740886-637A1248-27F7-4B3A-A5A4-91EC18C477B9Q33753287-B872C005-4A22-403A-8464-650D3E2E5CBBQ33890558-4D0F5FC6-3549-447B-9B1C-136E11834D24Q33968948-2BD1D932-B6D2-41AC-945D-3B87E403FDC2Q34004850-102CDA5C-41C2-4C5E-B4BE-25AC1C026A84Q34008192-C3B5CEBF-85B7-44D1-91BC-0C9AA94595A2Q34008245-22689A20-9A45-478C-9193-F0B6F30769B4Q34026328-B798E1B9-9A2B-4C53-8CE4-246AF0EDFEE1
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Harvey I Pass
@ast
Harvey I Pass
@en
Harvey I Pass
@es
Harvey I Pass
@nl
Harvey I Pass
@sl
ハーヴィー・I・パス
@ja
type
label
Harvey I Pass
@ast
Harvey I Pass
@en
Harvey I Pass
@es
Harvey I Pass
@nl
Harvey I Pass
@sl
ハーヴィー・I・パス
@ja
prefLabel
Harvey I Pass
@ast
Harvey I Pass
@en
Harvey I Pass
@es
Harvey I Pass
@nl
Harvey I Pass
@sl
ハーヴィー・I・パス
@ja
P1006
P214
P244
P1006
P106
P213
0000 0001 1749 7488
P214
P244
P2456
P31
P496
0000-0003-3222-3471
P734
P735
P7859
lccn-n82098035